Next&Bio
Latest round
- Series A
Last raised
- Apr 2020
Total raised
- $5.2M
Investors
- 5
About Next&Bio
Founded in 2018 and headquartered in Seoul, South Korea, Next&Bio develops patient-derived organoids for drug testing and molecular diagnostics.N Corporation and Hyundai Investment Partners.NEXT&BIO specializes in the development and provision of patient-derived organoids aimed at enabling personalized treatment methods. Their core offerings focus on organoid drug testing and molecular diagnostics, which provide high-precision disease models tailored to the specific needs of pharmaceutical companies, patients, and hospitals. By utilizing organoids, NEXT&BIO addresses critical challenges in drug development and validation, delivering more accurate and reliable results for therapeutic efficacy.NEXT&BIO's revenue model is structured around B2B transactions, where pharmaceutical companies and healthcare institutions partner with the firm to access its organoid testing services and disease models. The business transactions typically involve structured agreements that facilitate access to these high-value products tailored for drug development and clinical research. The company plans to expand its offerings and develop new products aimed at improving patient-derived organoid technologies. Future market expansion is targeted at increasing presence in North America and Europe by 2023, thereby enhancing its reach in the pharmaceutical and healthcare sectors.
Who invested in Next&Bio
5 investors across 1 round
See all investors in Next&Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Apr 3, 2020
Amount
$5.2M
Investors
Questions about Next&Bio
Who invested in Next&Bio?
Next&Bio has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Next&Bio raised?
Next&Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Next&Bio last raise money?
Next&Bio's most recent round on record is a Series A, in Apr 2020.
What does Next&Bio do?
Founded in 2018 and headquartered in Seoul, South Korea, Next&Bio develops patient-derived organoids for drug testing and molecular diagnostics.
Where is Next&Bio headquartered?
Next&Bio is headquartered in Seoul, South Korea.
Which VCs invest in companies like Next&Bio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Next&Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Next&Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.